Telix Pharmaceuticals Limited American Depositary Shares (TLX)
- CEO
- Christian Behrenbruch
- Headquarters
- United States
- Employees
- 1,184
- Market Cap
- $3.3B
About Telix Pharmaceuticals Limited American Depositary Shares
Telix is a developer of radiopharmaceuticals. Radiopharmaceuticals are specialized drugs containing radioactive isotopes, which are used in both diagnosing and treating cancer. At low doses, these drugs bind to a specific cancer cell and can be visualized through PET imaging. With high doses, they can deliver targeted treatment. Telix has a pipeline of both diagnostics and therapeutics in development. Its pipeline is focused on urologic oncology (prostate, kidney and bladder), neuro-oncology (glioma), musculoskeletal oncology and hematology. Currently, most of the firm's revenue comes from its Illuccix prostate cancer imaging/diagnostic agent.
SentiSense also tracks daily options readings for Telix Pharmaceuticals Limited American Depositary Shares: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Telix Pharmaceuticals Limited American Depositary Shares stock analysis, sentiment tracking, and market intelligence on SentiSense.